UB Paderborn / Katalog / Suche / in CDI

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory

British journal of dermatology (1951), 2014-03, Vol.170 (3), p.705-715

2014

Volltextzugriff (PDF)

Understanding Debriefing: A Qualitative Study of Event Reconstruction at an Academic Medical Center

Academic medicine, 2020-07, Vol.95 (7), p.1089-1097

2020

Volltextzugriff (PDF)

Encouraging Reflexivity in a Residency Leadership Development Program: Expanding Outside the Competency Approach

Academic medicine, 2018-02, Vol.93 (2), p.210-213

2018

Volltextzugriff (PDF)

188 Biologic immunotherapy and cancer recurrence in patients with psoriasis and a history of malignancy

Journal of investigative dermatology, 2024-08, Vol.144 (8), p.S33-S33

2024

Volltextzugriff (PDF)

Human and Porcine Islet Transplants in a New Double Capsule

The Journal of surgical research, 2013-02, Vol.179 (2), p.264-265

2013

Volltextzugriff (PDF)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

British journal of dermatology (1951), 2022-03, Vol.186 (3), p.466-475

2022

Volltextzugriff (PDF)

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study

Journal of the European Academy of Dermatology and Venereology, 2020-02, Vol.34 (2), p.301-309

2020

Volltextzugriff (PDF)

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3

British journal of dermatology (1951), 2018-08, Vol.179 (2), p.320-328

2018

Volltextzugriff (PDF)

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

Journal of the European Academy of Dermatology and Venereology, 2013-12, Vol.27 (12), p.1535-1545

2013

Volltextzugriff (PDF)

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

British journal of dermatology (1951), 2018-01, Vol.178 (1), p.132-139

2018

Volltextzugriff (PDF)

Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

Journal of the European Academy of Dermatology and Venereology, 2022-12, Vol.36 (12), p.2393-2400

2022

Volltextzugriff (PDF)

Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study

Journal of the European Academy of Dermatology and Venereology, 2018-11, Vol.32 (11), p.1940-1949

2018

Volltextzugriff (PDF)

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

British journal of dermatology (1951), 2012-04, Vol.166 (4), p.861-872

2012

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies

Journal of the American Academy of Dermatology, 2009-04, Vol.60 (4), p.643-659

2009

Volltextzugriff (PDF)

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

British journal of dermatology (1951), 2021-04, Vol.184 (4), p.652-662

2021

Volltextzugriff (PDF)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

Journal of the European Academy of Dermatology and Venereology, 2017-06, Vol.31 (6), p.1004-1013

2017

Volltextzugriff (PDF)

生物药物 ixekizumab 和 guselkumab 治疗中度至重度斑块型银屑病的比较研究

British journal of dermatology (1951), 2020-06, Vol.182 (6)

2020

Volltextzugriff (PDF)

Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2018-08, Vol.32 (8), p.1297-1304

2018

Volltextzugriff (PDF)

Defining drug‐free remission of skin disease in patients with plaque psoriasis

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.1484-1487

2020

Volltextzugriff (PDF)

Correlation of psoriasis activity with socioeconomic status: cross‐sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

British journal of dermatology (1951), 2018-10, Vol.179 (4), p.984-986

2018

Volltextzugriff (PDF)

生物药物 ixekizumab 和 guselkumab 治疗中度至重度斑块型银屑病的比较研究

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.e205-e205

2020

Volltextzugriff (PDF)

A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.e193-e193

2020

Volltextzugriff (PDF)

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab

Journal of the European Academy of Dermatology and Venereology, 2016-05, Vol.30 (5), p.864-865

2016

Volltextzugriff (PDF)

Proton Therapy in Head and Neck Cancer Treatment: State of the Problem and Development Prospects (Review)

Sovremennye tekhnologii v medit͡s︡ine, 2021-01, Vol.13 (4), p.70-80

2021

Volltextzugriff (PDF)

Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis

British journal of dermatology (1951), 2013-12, Vol.169 (6), p.1337-1341

2013

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory

Understanding Debriefing: A Qualitative Study of Event Reconstruction at an Academic Medical Center

Encouraging Reflexivity in a Residency Leadership Development Program: Expanding Outside the Competency Approach

188 Biologic immunotherapy and cancer recurrence in patients with psoriasis and a history of malignancy

Human and Porcine Islet Transplants in a New Double Capsule

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

生物药物 ixekizumab 和 guselkumab 治疗中度至重度斑块型银屑病的比较研究

Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis

Defining drug‐free remission of skin disease in patients with plaque psoriasis

Correlation of psoriasis activity with socioeconomic status: cross‐sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

生物药物 ixekizumab 和 guselkumab 治疗中度至重度斑块型银屑病的比较研究

A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab

Proton Therapy in Head and Neck Cancer Treatment: State of the Problem and Development Prospects (Review)

Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis

Suchergebnisse filtern